Compounds > etilevodopa
Page last updated: 2024-12-08

etilevodopa

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

etilevodopa: is the ethyl ester of levodopa; an antiparkinson drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID170345
CHEMBL ID1823681
CHEBI ID135971
SCHEMBL ID584493
MeSH IDM0460318

Synonyms (42)

Synonym
l-dopa ethyl ester
etilevodopa
tv-1203
levodopa ethyl ester
etilevodopa (usan/inn)
D04097
37178-37-3
CHEBI:135971
ethyl (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
CHEMBL1823681
895x917gye ,
unii-895x917gye
(-)-3,4-dihydroxy-l-phenylalanine, ethyl ester
etilevodopa [usan:inn]
o-ethyl-dopa
l-tyrosine, 3-hydroxy-, ethyl ester
AKOS015933284
AKOS010395756
3,4-dihydroxy-l-phenylalanine ethyl ester
etilevodopa [who-dd]
3-hydroxy-l-tyrosine ethyl ester
etilevodopa [inn]
3-hydroxy-tyrosine ethyl ester
etilevodopa [usan]
SCHEMBL584493
CCG-221888
2(s)-amino-3-(3,4-dihydroxyphenyl)propionic acid ethyl ester
mfcd00871210
F52325
l-dopa ethyl ester, >=98% (hplc)
NULMGOSOSZBEQL-QMMMGPOBSA-N
(s)-ethyl 2-amino-3-(3,4-dihydroxyphenyl)propanoate
DTXSID10905092
Q5404593
(s)-ethyl 2-amino-3-(3,4-dihydroxyphenyl)propanoate (h-l-tyr(3-oh)-oet)
CS-0063515
HY-116016
DB06535
ethyl (s)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
NCGC00408874-03
l-dopa ethyl ester;levodopa ethyl ester
EN300-150307

Research Excerpts

Overview

Etilevodopa is an ethyl-ester prodrug of levodopa. It has greater gastric solubility and passes quickly into the small intestine. It is rapidly hydrolyzed to levodOPA, and has a shortened time to maximum concentration.

ExcerptReferenceRelevance
"Etilevodopa is a unique, highly soluble prodrug of levodopa."( Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.
Djaldetti, R; Giladi, N; Hassin-Baer, S; Melamed, E; Shabtai, H, )		1.18
"Etilevodopa is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration."( A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.
Blindauer, K; Eyal, E; Fahn, S; Goetz, C; Goren, S; Kieburtz, K; Levy, R; Nutt, J; Oakes, D; Pagano, M; Salzman, P; Sayag, N; Schwid, S; Scolnik, M; Shoulson, I; Stern, M, 2006)		1.34

Pharmacokinetics

ExcerptReferenceRelevance
" To measure the maximal concentration (Cmax), time to Cmax (tmax), and area under the curve (AUC) of plasma levodopa, etilevodopa, and carbidopa, blood samples were drawn before drug administration and at intervals up to 240 minutes thereafter."( Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.
Djaldetti, R; Giladi, N; Hassin-Baer, S; Melamed, E; Shabtai, H, )		0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tyrosine derivativeAn amino acid derivative resulting from reaction of tyrosine at the amino group or the carboxy group, any substitution of phenyl hydrogens, or from the replacement of any hydrogen of tyrosine by a heteroatom. The definition normally excludes peptides containing tyrosine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID615024Half life in human plasma2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
QSAR models for predicting enzymatic hydrolysis of new chemical entities in 'soft-drug' design.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.13 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (33.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
propantheline
Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.		2.0510xanthenes
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		3.8821amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
acetyl sulfisoxazole
[no description available]		2.0510benzenes;
sulfonamide
glycyl-l-phenylalanine
glycylphenylalanine: RN given refers to (DL)-isomer. Gly-Phe : A dipeptide formed from glycine and L-phenylalanine residues.		2.0510dipeptide zwitterion;
dipeptide		human metabolite;
metabolite
enkephalin, leucine
Enkephalin, Leucine: One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.. Leu-enkephalin : A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.		2.0510pentapeptide;
peptide zwitterion		analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite
enkephalin, leucine-2-alanine
Enkephalin, Leucine-2-Alanine: A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.		2.0510
valacyclovir
Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.		2.0510L-valyl esterantiviral drug
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Idiopathic Parkinson Disease
[description not available]		03.4111
Developmental Coordination Disorder
[description not available]		03.4111
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		08.4111